The Lindsay Clancy case shows the limits of postpartum psychiatry Treatment options are limited, diagnosis is complicated, and the science is unfinished

https://www.statnews.com/2026/08/12/lindsay-clancy-postpartum-psychosis-diagnosis-treatment-limits/ By Jamie Maguire, Lauren M. Osborne, and Jennifer PayneAug. 12, 2026 Maguire is a professor of neuroscience at Tufts University School of Medicine. Osborne is an associate professor of obstetrics and gynecology and psychiatry and a reproductive psychiatrist at NewYork-Presbyterian and Weill Cornell Medicine. Payne is vice chair of research and a professor at the University of Virginia in the Department of Psychiatry and Neurobehavioral Sciences, as well as the director of the Reproductive Psychiatry Research Program, UVA Health.

Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies Georg Schett, known for CAR-T work, moves in a new direction

https://www.statnews.com/2026/08/12/boulevard-bio-georg-schett-antibody-therapies/ By Allison DeAngelisAug. 12, 2026 Biotech Startups and Venture Capital Reporter

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say New therapy for Prader-Willi syndrome is linked to reports of deaths, severe side effects

https://www.statnews.com/2026/08/12/neurocrine-biosciences-vykat-prader-willi/ By Adam FeuersteinAug. 12, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

1 year of The Lancet Primary Care The Lancet Primary Care +... +

1 year of The Lancet Primary Care The Lancet Primary Care https://www.thelancet.com/journals/lanprc/issue/vol2no7/PIIS3050-5143(26)X2007-6 Weight status and pathways to eating disorder referral from primary care in England and Northern Ireland: a cross-sectional analysis of routine care data Chloe Gao, BHSca,b,∗ Send email to gaoc1234@student.ubc.ca ∙ Jessica Wilkins, MEda,∗ ∙ Alex Dregan, PhDc ∙ Karina L Allen, PhDa,d ∙ Jamie Scuffell, MBChBe ∙ Prof Ulrike Schmidt, MD PhD https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00075-0/fulltext?dgcid=raven_jbs_etoc_feature_lanprc

The mechanism debate in psilocybin therapy for depression eBioMedicine +... + +

The mechanism debate in psilocybin therapy for depression eBioMedicine https://www.thelancet.com/journals/ebiom/issue/vol130nonull/PIIS2352-3964(26)X2006-0 Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men Hatim Kernissa,b,c Send email to Kerniss@med.uni-frankfurt.de ∙ Philip Curmanb,d,e,f ∙ Henning Olbrichg ∙ Khalaf Kridinb,h,i ∙ Rohin Francisj ∙ David M. Leistnera,c ∙ et al. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00256-2/fulltext?dgcid=raven_jbs_etoc_feature_ebiom Microcephaly-like phenotype triggered by novel reassortant and prototypic Oropouche virus strains in brain organoids Gabrielle Bruma,k ∙ Vivian Grizentea,k ∙ Fábio Luís Lima Monteirob,k ∙ Beatriz Luzia de Mello Lima Guimarãesa ∙ Livia Goto-Silvaa ∙ João Marcos de Azevedo Deloua ∙ et al. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00292-6/fulltext?dgcid=raven_jbs_etoc_feature_ebiom

Calla Lily joins $50M program targeting antibiotic resistance A new intravaginal drug delivery platform has been selected to investigate whether localized UTI treatment can reduce the collateral effects of systemic antibiotics. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/calla-lily-joins-50m-program-targeting-antibiotic-resistance-17427 Antimicrobial resistance (AMR) is increasingly recognized as a consequence not only of antibiotic-resistant bacteria, but also of the collateral effects of antibiotic treatment. Antibiotic administration can profoundly alter the composition and diversity of the gut microbiota, disrupt homeostasis, and create selective pressure that promotes the proliferation of antibiotic-resistant bacteria. According to Wellcome Leap, 85–90 percent of bacterial infections are localized, while nearly all antibiotics are delivered systemically.

Immunotherapy drug successfully reduced antibodies to allow kidney transplantation The newly approved drug vastly reduced the amount of antibodies that would usually lead to organ rejection in a patient who had no chance of receiving a matched transplant. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/immunotherapy-drug-successfully-reduced-antibodies-to-allow-kidney-transplantation-17424 A 37-year-old man who once had no hope of receiving a matched donor kidney is now living dialysis-free with a new kidney that has excellent function. After spending 12 years on an organ waiting list, the joyful outcome came thanks to a new drug recently approved from Johnson & Johnson to treat multiple myeloma, called teclistamab. The drug is a bispecific T cell engager antibody that works by activating T cells and binding to B-cell maturation antigen (BCMA) on the target cells to tag them for destruction.